Application of the Pancreatic Adenocarcinoma Staging System to Pancreatic Neuroendocrine Tumors
- 31 October 2007
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American College of Surgeons
- Vol. 205 (4), 558-563
- https://doi.org/10.1016/j.jamcollsurg.2007.05.009
Abstract
The American Joint Committee on Cancer (AJCC) 6th edition staging system for pancreatic adenocarcinoma specifically excludes pancreatic neuroendocrine tumors (PNETs), and a widely accepted staging classification does not exist. Our objective was to evaluate the feasibility of applying the AJCC pancreatic adenocarcinoma staging system to PNETs. Patients with PNETs were identified from the National Cancer Data Base (1985 to 2004). Overall survival was estimated using the Kaplan-Meier method and compared using the log-rank test. Cox proportional hazards modeling was used to evaluate the effect of tumor size, nodal status, and distant metastases on survival. Of 4,793 patients with PNETs, 93.6% were of islet cell origin, and 6.4% were carcinoid tumors; 1,815 (37.9%) underwent resection. Overall 5-year survival rates were 29.2% for all patients, 55.4% for resected patients, and 15.6% for unresected patients. The AJCC staging system provided good prognostic survival discrimination between stage groups for resected patients (p < 0.0001). When comparing outcomes to those of patients with pancreatic adenocarcinoma, the estimated median survival was significantly better for resected patients with PNETs (60 versus 13 months, p < 0.0001). Distant metastasis was the only independent predictor of survival (p < 0.0001). When applied to PNETs, the AJCC staging system for pancreatic adenocarcinoma provides survival discrimination by stage for surgical and nonsurgical patients. Survival rates are better for PNETs than for pancreatic adenocarcinoma, but the staging system can effectively stratify patients with PNETs.Keywords
This publication has 14 references indexed in Scilit:
- An Aggressive Surgical Approach Leads to Long-term Survival in Patients With Pancreatic Endocrine TumorsAnnals of Surgery, 2006
- Resection of Pancreatic Neuroendocrine TumorsArchives of Surgery, 2006
- Surgery for Primary Pancreatic Neuroendocrine TumorsJournal of Gastrointestinal Surgery, 2006
- Neuroendocrine Tumours of the Pancreas: Predictors of Survival after Surgical TreatmentDigestive Surgery, 2005
- Differences in Survival by Histologic Type of Pancreatic CancerCancer Epidemiology, Biomarkers & Prevention, 2005
- Is the New Classification of Neuroendocrine Pancreatic Tumors of Clinical Help?World Journal of Surgery, 2000
- Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patientsJournal of Gastrointestinal Surgery, 1998
- Determinants of metastatic rate and survival in patients with zollinger-ellison syndrome: A prospective long-term studyGastroenterology, 1995
- Revised classification of neuroendocrine tumours of the lung, pancreas and gutVirchows Archiv A Pathological Anatomy and Histopathology, 1995
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958